Pub. Date : 2015 Jan 6
PMID : 25422908
1 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | BACKGROUND: Sunitinib (VEGFR/PDGFR inhibitor) and everolimus (mTOR inhibitor) are both approved for advanced renal cell carcinoma (RCC) as first-line and second-line therapy, respectively. | Sunitinib | kinase insert domain receptor | Homo sapiens |